Drug Retail

Jefferies & Company has raised the price target on Walgreen Company (NYSE: WAG) from $48 to $50 and maintains its Buy rating.

J.P. Morgan lowered its CVS Caremark (NYSE: CVS) price target to $42 from $45 in a research report published today. In the report, J.P. Morgan states, "The key question after CVS's disappointing 2011 guidance is whether the stock is a compelling value or a value trap. While the latter has been true...

JP Morgan has lowered the price target on CVS Caremark Corporation (NYSE: CVS) from $45 to $42 and maintains its Overweight rating.

CVS Caremark(CVS) reported an adjusted EPS of 80 cents in the fourth quarter of fiscal 2010, beating both the Zacks Consensus Estimate and the year-ago period by a penny. For the full year, the adjusted EPS of $2.69 was in line with the Zacks Consensus Estimate. However, the EPS declined compared...

CVS Caremark(CVS) reported an adjusted EPS of 80 cents in the fourth quarter of fiscal 2010, beating both the Zacks Consensus Estimate and the year-ago period by a penny. For the full year, the adjusted EPS of $2.69 was in line with the Zacks Consensus Estimate. However, the EPS declined compared...

Walgreens (NYSE: WAG) (NASDAQ: WAG) had January sales of $5.93 billion, an increase of 11.3 percent from $5.33 billion for the same month in 2010. Duane Reade stores, acquired in April 2010, contributed 2.8 percentage points to the total sales increase for the month. Sales in comparable stores (...

Woonsocket, Rhode Island-based CVS Caremark Corporation (NYSE: CVS) released financial results on Thursday morning that beat Wall Street earnings estimates, while failing to meet revenue expectations. CVS Caremark Corporation announced that its 4th quarter net income fell to $1.03 billion, or 75...

Analysts at Citigroup upgrade Walgreen Company (NYSE: WAG) from “sell” to “hold.” The target price for WAG has been raised from $33 to $43. WAG shares surged 4.43% to close at $42.23 yesterday. More Analyst Ratings here

J.P. Morgan is out with its report on CVS Caremark (NYSE: CVS), reiterating Overweight in anticipation of CVS reporting Q4 10 results this Thursday. In a note to clients, J.P. Morgan writes, "Overall, we believe CVS Caremark could deliver 4Q10 EPS at or above expectations, driven by potential...

Rite Aid Corp. (RAD) posted a quarterly loss of $0.09 a share for the third quarter of fiscal 2011, which was an improvement over Zacks Consensus Estimate of a loss of $0.13. Wal-Mart's foray into the retail generic drug market is putting pressure on Rite Aid's pharmacy margin. Moreover, an...

Rite Aid Corp. (RAD) posted a quarterly loss of $0.09 a share for the third quarter of fiscal 2011, which was an improvement over Zacks Consensus Estimate of a loss of $0.13. Wal-Mart's foray into the retail generic drug market is putting pressure on Rite Aid's pharmacy margin. Moreover, an...

Leading drugstore chain operator Rite Aid Corp. (RAD) reported growth of 1.1% in same-store sales for the four weeks ended January 22, 2011. The company reported two consecutive months of same-store sales increase after 18 consecutive months of decline ever since May 2009, when it had registered...

Leading drugstore chain operator Rite Aid Corp. (RAD) reported growth of 1.1% in same-store sales for the four weeks ended January 22, 2011. The company reported two consecutive months of same-store sales increase after 18 consecutive months of decline ever since May 2009, when it had registered...

Goldman Sachs has a Buy rating and a $42 price target on shares of CVS Caremark Corporation (NYSE: CVS). In a note to clients, Goldman writes, "When CVS reports earnings on February 3rd, we expect the focus will be on the path through a choppy 2011 to a big payout in 2012. We advocate owning this...

Here's what Benzinga's reading on our friend, TheStreet.com. What's Hot On TheStreet S&P Touches 1300, Dow Past 12,000 Stocks advanced Thursday as the S&P 500 touched the 1,300 level and the Dow Jones Industrial Average passed the 12,000 mark for the second consecutive session. Pending-...